Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PF-07321332/ritonavir in Healthy Chinese Participants
NCT05339334Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2022
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Primary endpoints: PF-07321332 Maximum Observed Plasma Concentration at Day 10, PF-07321332 Time for Maximum Observed Plasma Concentration at Day 10 and 11 more. Started Mar 2022; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05339334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05339334.